Clinical Trials Browser

INDUSTRY × Erlotinib Hydrochloride × 1 year × Clear all

NCT04449874 2026-02-12

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

Phase 1 Active not recruiting

498 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Colorectal Neoplasms

NCT02152631 2026-02-06

JUNIPER

Phase 3 Active not recruiting

453 enrolled 18 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05827614 2026-01-23

POTENTIATE

Phase 1 Active not recruiting

85 enrolled

BreastHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Leiomyosarcoma, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02411448 2026-01-16

RELAY

Phase 3 Active not recruiting

545 enrolled 24 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00596648 2026-01-13

A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Completed

92 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02296125 2026-01-09

FLAURA

Phase 3 Completed

674 enrolled 21 charts 1 FDA

Thoracic

Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer

NCT07271446 2025-12-09

An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer

Phase 1 Completed

8 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03498521 2025-11-19

CUPISCO

Phase 2 Completed

529 enrolled 16 charts

Tumor-Agnostic

Neoplasms, Unknown Primary

NCT01186861 2025-11-18

Phase 2 Study of Maintenance OSI-906 Plus Erlotinib (Tarceva®), or Placebo Plus Erlotinib in Patients With Nonprogression Following 4 Cycles of Platinum-based Chemotherapy

Phase 2 Completed

205 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01221077 2025-11-18

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

Phase 2 Completed

88 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00600496 2025-11-13

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Active not recruiting

140 enrolled

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT03653546 2025-09-10

BM

Phase 2/3 Completed

492 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Respiratory Tract Diseases

NCT02099058 2025-08-14

A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors

Phase 1 Active not recruiting

237 enrolled

Tumor-Agnostic

Neoplasms

NCT05442060 2025-08-03

EGFR

Phase 2 Recruiting

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02991651 2025-05-14

Study of IRX4204 With Erlotinib in Previously Treated Advanced NSCLC

Phase 1 Terminated

12 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung